@article {20371,
	title = {A global scientific strategy to cure hepatitis B},
	journal = {Lancet Gastroenterol HepatolLancet Gastroenterol HepatolLancet Gastroenterol Hepatol},
	volume = {4},
	number = {7},
	year = {2019},
	note = {2468-1253Revill, Peter AChisari, Francis VBlock, Joan MDandri, MauraGehring, Adam JGuo, HaitaoHu, JianmingKramvis, AnnaLampertico, PietroJanssen, Harry L ALevrero, MassimoLi, WenhuiLiang, T JakeLim, Seng-GeeLu, FengminPenicaud, M CapucineTavis, John EThimme, RobertMembers of the ICE-HBV Working GroupsICE-HBV Stakeholders Group ChairsICE-HBV Senior AdvisorsZoulim, FabienR01 AI134818/AI/NIAID NIH HHS/United StatesR01 AI127670/AI/NIAID NIH HHS/United StatesR01 AI123271/AI/NIAID NIH HHS/United StatesR37 AI043453/AI/NIAID NIH HHS/United StatesR01 AI043453/AI/NIAID NIH HHS/United StatesR01 AI110762/AI/NIAID NIH HHS/United StatesJournal ArticleResearch Support, N.I.H., IntramuralLancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10.},
	month = {Jul},
	pages = {545-558},
	edition = {2019/04/15},
	abstract = {Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key stakeholders including people affected by HBV, we have identified gaps in our current knowledge and new strategies and tools that are required to achieve HBV cure. We believe that research must focus on the discovery of interventional strategies that will permanently reduce the number of productively infected cells or permanently silence the covalently closed circular DNA in those cells, and that will stimulate HBV-specific host immune responses which mimic spontaneous resolution of HBV infection. There is also a pressing need for the establishment of repositories of standardised HBV reagents and protocols that can be accessed by all HBV researchers throughout the world. The HBV cure research agenda outlined in this position paper will contribute markedly to the goal of eliminating HBV infection worldwide.},
	keywords = {Animals, Antiviral Agents/therapeutic use, B-Lymphocytes/immunology, Cell Line, Transformed, Disease Eradication/methods, Disease Models, Animal, DNA, Viral/drug effects, Forecasting, Global Health, Hepatitis B virus/immunology/physiology, Hepatitis B, Chronic/immunology/*prevention \& control/virology, Hepatocytes/virology, Humans, Immunity, Cellular, Immunotherapy/methods/trends, Liver Neoplasms/prevention \& control, Remission Induction, Research, T-Lymphocytes/immunology, Virus Replication/physiology},
	author = {Revill, P. A. and Chisari, F. V. and Block, J. M. and Dandri, M. and Gehring, A. J. and Guo, H. and Hu, J. and Kramvis, A. and Lampertico, P. and Janssen, H. L. A. and Levrero, M. and Li, W. and Liang, T. J. and Lim, S. G. and Lu, F. and Penicaud, M. C. and Tavis, J. E. and Thimme, R. and Zoulim, F.}
}
